| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $452,996 ) |
| | 2025 | 2025 | PAI LIFE SCIENCES INC | 1551 EASTLAKE AVE E STE 250 | SEATTLE | WA | 98102-7402 | KING | USA | R44AI140708 | A Vaccine for Lymphatic Filariasis, LFGuard™ | 002 | 6 | NIH | 3/21/2025 | $452,996 |
| | 2025 | 2024 | PAI LIFE SCIENCES INC | 1551 EASTLAKE AVE E STE 250 | SEATTLE | WA | 98102-7402 | KING | USA | R44AI140708 | A Vaccine for Lymphatic Filariasis, LFGuard™ | 001 | 5 | NIH | 11/26/2024 | $939,768 |
| | 2025 | 2022 | PAI LIFE SCIENCES INC | 1551 EASTLAKE AVE E STE 250 | SEATTLE | WA | 98102-7402 | KING | USA | R44AI103983 | A Vaccine for Schistosomiasis, "SchistoShield" | 000 | 8 | NIH | 4/23/2025 | $0 |
| | 2025 | 2022 | PAI LIFE SCIENCES INC | 1551 EASTLAKE AVE E STE 250 | SEATTLE | WA | 98102-7402 | KING | USA | R44AI140708 | A Vaccine for Lymphatic Filariasis, LFGuard™ | 000 | 4 | NIH | 11/26/2024 | -$939,768 |
|
| Issue Date FY: 2024 ( Subtotal = $1,275,803 ) |
| | 2024 | 2024 | PAI LIFE SCIENCES INC | 1616 EASTLAKE AVE E | SEATTLE | WA | 98102-3788 | KING | USA | R41AI181069 | Antigen and adjuvant selection for a vaccine against urogenital schistosomiasis, Hematoshield | 000 | 1 | NIH | 1/3/2024 | $295,386 |
| | 2024 | 2024 | PAI LIFE SCIENCES INC | 1616 EASTLAKE AVE E | SEATTLE | WA | 98102-3788 | KING | USA | R44AI140708 | A Vaccine for Lymphatic Filariasis, LFGuard™ | 001 | 5 | NIH | 12/8/2023 | $995,460 |
| | 2024 | 2023 | PAI LIFE SCIENCES INC | 1616 EASTLAKE AVE E | SEATTLE | WA | 98102-3788 | KING | USA | R43AI179364 | Evaluation of a Next Generation SchistoShield Vaccine | 000 | 1 | NIH | 10/17/2023 | $0 |
| | 2024 | 2022 | PAI LIFE SCIENCES INC | 1616 EASTLAKE AVE E | SEATTLE | WA | 98102-3788 | KING | USA | R44AI103983 | A Vaccine for Schistosomiasis, "SchistoShield" | 000 | 8 | NIH | 3/28/2024 | $0 |
| | 2024 | 2022 | PAI LIFE SCIENCES INC | 1616 EASTLAKE AVE E | SEATTLE | WA | 98102-3788 | KING | USA | R44AI140708 | A Vaccine for Lymphatic Filariasis, LFGuard™ | 000 | 4 | NIH | 11/30/2023 | $0 |
| | 2024 | 2021 | PAI LIFE SCIENCES INC | 1551 EASTLAKE AVE E STE 250 | SEATTLE | WA | 98102-7402 | KING | USA | R21AI151824 | Developing a Screen for New Adjuvants to Enhance RNA Vaccines | 000 | 2 | NIH | 3/11/2024 | -$15,043 |
| | 2024 | 2021 | PAI LIFE SCIENCES INC | 1551 Eastlake Ave E Ste 250 | Seattle | WA | 98102-7402 | KING | USA | R43IP001164 | Adjuvanted Recombinant Candidates to Prime / Boost COVID-19 RNA Vaccines | 04 | 1 | CDC | 9/18/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $300,000 ) |
| | 2023 | 2023 | PAI LIFE SCIENCES INC | 1616 EASTLAKE AVE E | SEATTLE | WA | 98102-3788 | KING | USA | R43AI179364 | Evaluation of a Next Generation SchistoShield Vaccine | 000 | 1 | NIH | 9/12/2023 | $300,000 |
| | 2023 | 2020 | PAI LIFE SCIENCES INC | 1616 EASTLAKE AVE E | SEATTLE | WA | 98102-3788 | KING | USA | R44CA206607 | JOC-x: Chemotherapy conjugates that open tumor tight junctions to treat cancer | 000 | 3 | NIH | 8/14/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,506,495 ) |
| | 2022 | 2022 | PAI LIFE SCIENCES, INC. | 1616 EASTLAKE AVE E STE 250 | SEATTLE | WA | 98102-3739 | KING | USA | R44AI140708 | A Vaccine for Lymphatic Filariasis, LFGuard™ | 000 | 4 | NIH | 5/18/2022 | $1,000,000 |
| | 2022 | 2022 | PAI LIFE SCIENCES, INC. | 1616 EASTLAKE AVE E STE 250 | SEATTLE | WA | 98102-3739 | KING | USA | R44AI103983 | A Vaccine for Schistosomiasis, "SchistoShield" | 000 | 8 | NIH | 2/3/2022 | $506,495 |
| | 2022 | 2021 | PAI LIFE SCIENCES, INC. | 1616 Eastlake Ave E Ste 250 | Seattle | WA | 98102-3739 | KING | USA | R43IP001164 | Adjuvanted Recombinant Candidates to Prime / Boost COVID-19 RNA Vaccines | 02 | 1 | CDC | 9/15/2022 | $0 |
| | 2022 | 2021 | PAI LIFE SCIENCES, INC. | 1616 Eastlake Ave E Ste 250 | Seattle | WA | 98102-3739 | KING | USA | R43IP001164 | Adjuvanted Recombinant Candidates to Prime / Boost COVID-19 RNA Vaccines | 01 | 1 | CDC | 9/14/2022 | $0 |
| | 2022 | 2021 | PAI LIFE SCIENCES, INC. | 1616 Eastlake Ave E Ste 250 | Seattle | WA | 98102-3739 | KING | USA | R43IP001164 | Adjuvanted Recombinant Candidates to Prime / Boost COVID-19 RNA Vaccines | 03 | 1 | CDC | 9/20/2022 | $0 |
| | 2022 | 2019 | PAI LIFE SCIENCES, INC. | 1616 EASTLAKE AVE E STE 250 | SEATTLE | WA | 98102-3739 | KING | USA | R43AI142908 | Production and Validation of Sj-p80 as a Veterinary Schistosomiasis Vaccine | 000 | 1 | NIH | 4/25/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,824,399 ) |
| | 2021 | 2021 | PAI LIFE SCIENCES, INC. | 1616 EASTLAKE AVE E STE 250 | SEATTLE | WA | 98102-3739 | KING | USA | R21AI151824 | Developing a Screen for New Adjuvants to Enhance RNA Vaccines | 002 | 2 | NIH | 5/14/2021 | -$87,217 |
| | 2021 | 2021 | PAI LIFE SCIENCES, INC. | 1616 EASTLAKE AVE E STE 250 | SEATTLE | WA | 98102-3739 | KING | USA | R21AI151824 | Developing a Screen for New Adjuvants to Enhance RNA Vaccines | 001 | 2 | NIH | 4/26/2021 | $87,217 |
| | 2021 | 2021 | PAI LIFE SCIENCES, INC. | 1616 EASTLAKE AVE E STE 250 | SEATTLE | WA | 98102-3739 | KING | USA | R44AI140708 | A Vaccine for Lymphatic Filariasis, LFGuard™ | 000 | 3 | NIH | 5/21/2021 | $1,000,000 |
| | 2021 | 2021 | PAI LIFE SCIENCES, INC. | 1616 EASTLAKE AVE E STE 250 | SEATTLE | WA | 98102-3739 | KING | USA | R21AI151824 | Developing a Screen for New Adjuvants to Enhance RNA Vaccines | 003 | 2 | NIH | 6/25/2021 | -$426 |
| | 2021 | 2021 | Pai Life Sciences, Inc. | 1616 Eastlake Ave E Ste 250 | Seattle | WA | 98102-3739 | KING | USA | R43IP001164 | Adjuvanted Recombinant Candidates to Prime / Boost COVID-19 RNA Vaccines | 00 | 1 | CDC | 9/8/2021 | $243,000 |
| | 2021 | 2021 | PAI LIFE SCIENCES, INC. | 1616 EASTLAKE AVE E STE 550 | SEATTLE | WA | 98102-3788 | KING | USA | R44AI103983 | A Vaccine for Schistosomiasis, "SchistoShield" | 000 | 7 | NIH | 2/4/2021 | $506,495 |
| | 2021 | 2021 | PAI LIFE SCIENCES, INC. | 1616 EASTLAKE AVE E STE 250 | SEATTLE | WA | 98102-3739 | KING | USA | R21AI151824 | Developing a Screen for New Adjuvants to Enhance RNA Vaccines | 002 | 2 | NIH | 5/14/2021 | $87,217 |
| | 2021 | 2020 | PAI LIFE SCIENCES, INC. | 1616 EASTLAKE AVE E STE 250 | SEATTLE | WA | 98102-3739 | KING | USA | R21AI151824 | Developing a Screen for New Adjuvants to Enhance RNA Vaccines | 000 | 1 | NIH | 4/23/2021 | -$11,887 |
| | 2021 | 2019 | PAI LIFE SCIENCES, INC. | 1616 EASTLAKE AVE E STE 250 | SEATTLE | WA | 98102-3739 | KING | USA | R43AI140708 | Process Development for a Lymphatic Filariasis Vaccine, (LFGuard?) | 000 | 1 | NIH | 5/24/2021 | $0 |
| | 2021 | 2019 | PAI LIFE SCIENCES, INC. | 1616 EASTLAKE AVE E STE 550 | SEATTLE | WA | 98102-3788 | KING | USA | R43AI142908 | Production and Validation of Sj-p80 as a Veterinary Schistosomiasis Vaccine | 000 | 1 | NIH | 12/23/2020 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $2,565,174 ) |
| | 2020 | 2020 | PAI LIFE SCIENCES, INC. | 1616 EASTLAKE AVE E STE 550 | SEATTLE | WA | 98102-3788 | KING | USA | R44CA206607 | JOC-x: Chemotherapy conjugates that open tumor tight junctions to treat cancer | 000 | 3 | NIH | 8/26/2020 | $556,615 |
| | 2020 | 2020 | PAI LIFE SCIENCES, INC. | 1616 EASTLAKE AVE E STE 550 | SEATTLE | WA | 98102-3788 | KING | USA | R44AI103983 | A Vaccine for Schistosomiasis, "SchistoShield" | 001 | 6 | NIH | 3/12/2020 | $706,627 |
| | 2020 | 2020 | PAI LIFE SCIENCES, INC. | 1616 EASTLAKE AVE E STE 550 | SEATTLE | WA | 98102-3788 | KING | USA | R44AI140708 | A Vaccine for Lymphatic Filariasis, LFGuard™ | 000 | 2 | NIH | 6/23/2020 | $1,000,000 |
| | 2020 | 2020 | PAI LIFE SCIENCES, INC. | 1616 EASTLAKE AVE E STE 550 | SEATTLE | WA | 98102-3788 | KING | USA | R21AI151824 | Developing a Screen for New Adjuvants to Enhance RNA Vaccines | 000 | 1 | NIH | 6/11/2020 | $301,932 |
| | 2020 | 2019 | PAI LIFE SCIENCES, INC. | 1616 EASTLAKE AVE E STE 550 | SEATTLE | WA | 98102-3788 | KING | USA | R43AI140708 | Process Development for a Lymphatic Filariasis Vaccine, (LFGuard?) | 000 | 1 | NIH | 6/15/2020 | $0 |
| | 2020 | 2018 | PAI LIFE SCIENCES, INC. | 1616 EASTLAKE AVE E STE 550 | SEATTLE | WA | 98102-3788 | KING | USA | R44AI103983 | A Vaccine for Schistosomiasis, "SchistoShield" | 000 | 5 | NIH | 3/2/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,148,830 ) |
| | 2019 | 2019 | PAI LIFE SCIENCES, INC. | 1616 EASTLAKE AVE E STE 550 | SEATTLE | WA | 98102-3788 | KING | USA | R44CA206607 | JOC-x: Chemotherapy conjugates that open tumor tight junctions to treat cancer | 000 | 2 | NIH | 9/19/2019 | $720,945 |
| | 2019 | 2019 | PAI LIFE SCIENCES, INC. | 1616 EASTLAKE AVE E STE 550 | SEATTLE | WA | 98102-3788 | KING | USA | R43AI142908 | Production and Validation of Sj-p80 as a Veterinary Schistosomiasis Vaccine | 000 | 1 | NIH | 11/19/2018 | $224,999 |
| | 2019 | 2019 | PAI LIFE SCIENCES, INC. | 1616 EASTLAKE AVE E STE 550 | SEATTLE | WA | 98102-3788 | KING | USA | R43AI140708 | Process Development for a Lymphatic Filariasis Vaccine, (LFGuard?) | 000 | 1 | NIH | 2/27/2019 | $224,988 |
| | 2019 | 2017 | PAI LIFE SCIENCES, INC. | 1616 EASTLAKE AVE E STE 550 | SEATTLE | WA | 98102-3788 | KING | USA | R43AI127053 | Development of an Innovative, Effective RNA-based Vaccine for Chikungunya Virus | 000 | 1 | NIH | 5/7/2019 | -$22,102 |
| | 2019 | 2017 | PAI LIFE SCIENCES, INC. | 1616 EASTLAKE AVE E STE 550 | SEATTLE | WA | 98102-3788 | KING | USA | R41AI134271 | CruziScreen, a recombinant antigen-based screening test for Chagas disease | 000 | 1 | NIH | 4/18/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $1,288,089 ) |
| | 2018 | 2018 | PAI LIFE SCIENCES, INC. | 1616 EASTLAKE AVE E STE 550 | SEATTLE | WA | 98102-3788 | KING | USA | R44AI103983 | A Vaccine for Schistosomiasis, "SchistoShield" | 000 | 5 | NIH | 12/29/2017 | $1,288,089 |
| | 2018 | 2016 | PAI LIFE SCIENCES, INC. | 1616 EASTLAKE AVE E STE 550 | SEATTLE | WA | 98102-3788 | KING | USA | R43CA206607 | JOC-x: Chemotherapy conjugates that open tumor tight junctions to treat cancer | 000 | 1 | NIH | 5/22/2018 | $0 |
|
|
